Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07594119
PHASE3

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Sponsor: Rapport Therapeutics Inc.

View on ClinicalTrials.gov

Summary

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

312

Start Date

2026-09

Completion Date

2029-09

Last Updated

2026-09-02

Healthy Volunteers

No

Interventions

DRUG

RAP-219

RAP-219 medium dose tablets administered orally daily

DRUG

RAP-219

RAP-219 low dose tablets administered orally daily

OTHER

Placebo

Matching placebo tablets administered orally

Locations (11)

Clinic for Neurology

Huntsville, Alabama, United States

Pillar Clinical Research

Bentonville, Arkansas, United States

Colorado Springs Neurological Associates

Colorado Springs, Colorado, United States

K2 Medical Research

Maitland, Florida, United States

Serenity Research Center, LLC

Miami, Florida, United States

Re:Cognition Health-Chicago

Chicago, Illinois, United States

Lenox Hill Hospital

New York, New York, United States

Velocity Clinical Research

Raleigh, North Carolina, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Baylor College of Medicine

Houston, Texas, United States

University of Texas Health Science Center in Houston

Houston, Texas, United States